Diabeloop and EOFlow announced that they partnered to offer the latter’s EOPatch system with automated insulin delivery in Europe.
This partnership combines the EOPatch, a third-party continuous glucose monitor (CGM) and Diabeloop’s automated insulin delivery algorithm. They all integrate into Diabeloop’s currently under-development smartphone app.
Paris-based Diabeloop said in a news release that they also plan to integrate EOPatch into its DBLG1 system. This would integrate the algorithm into a dedicated handset.
“It is an honor to partner with EOFlow and combine our state-of-the-art automated insulin delivery algorithm with their innovative wearable insulin pump solution. Diabeloop and EOFlow share the same goal to offer choices to people living with diabetes by providing advanced and user-friendly solutions,” said Diabeloop co-founder and CEO Herik Huneker. “We confirmed the technical feasibility of our integration through a Hackathon last summer, and we are expanding this as an official development agreement to commercialize a combined solution.”
More on the Diabeloop-EOFlow partnership
All three components of the planned automated insulin delivery system already received CE mark in Europe. The companies say they could offer the technology to patients “soon after” completing the development. Diabeloop earmarked a commercial launch for the end of 2023.
Diabeloop has ongoing discussions with several device manufacturers while it develops its smartphone app. It expects EOFlow’s disposable, tubeless insulin pump offering with app controls to “feed a great need” of patients.
EOFlow launched its EOPatch insulin delivery system in Korea and Europe. The company also recently announced that it seeks U.S. FDA clearance.
“In the field of automated insulin delivery, the adaptability and scalability of our wearable insulin pump is limitless, and we are working toward placing ourselves in a leadership position,” said Jesse J. Kim, EOFlow founder and CEO. “While we continue to commercialize EOPatch X, our artificial pancreas solution, we’re excited to kick off this partnership with Diabeloop and bring a wearable AID option to users sooner. We are also eager to make the smartphone app available in the European market.”